Kyle Habet, MD

Kyle Habet, MD, is a physician at Belize International Institute of Neuroscience where he is a member of a multidisciplinary group of healthcare professionals involved in the care of patients with an array of neurological and psychiatric diseases. He is a published author, researcher and instructor of neuroscience and clinical medicine at Washington University of Health and Science.

All articles by Kyle Habet, MD

Features, HAE Features

Considerations for Treating Women With HAE: Lessons From a Puzzling Type 3 Case

Kyle Habet, MD

August 5, 2022

There are a few considerations that physicians need to make when caring for female patients with HAE-C1INH type I or II or HAE-nl-C1INH.

Features, IPF Features

Updated Clinical Practice Guidelines Provide Strategies for Diagnosing and Treating IPF

Kyle Habet, MD

June 21, 2022

An updated set of clinical practice guidelines has been issued for the diagnosis and treatment of idiopathic pulmonary fibrosis in adults.

Features, SM Features

Lessons to Be Learned From Rare Presentations of Systemic Mastocytosis

Kyle Habet, MD

June 16, 2022

The diagnosis of systemic mastocytosis is particularly challenging when cutaneous symptoms are absent.

Features, SCD Features

An Often Overlooked Disease Exiting the Shadows

Kyle Habet, MD

January 10, 2022

Funding for sickle cell disease clinical trials and drug development has steadily increased and groundbreaking gene therapy research is being conducted.

Features, MS Features

Bridging the Diagnostic Gap in Multiple Sclerosis

Kyle Habet, MD

October 5, 2021

Multiple sclerosis (MS) is the most common immune-mediated demyelinating disease of the central nervous system (CNS). It is also characterized by inflammation and axonal degeneration in the CNS and is vastly heterogeneous in its presentation.1 Diagnosis of MS has improved over time; however, there is still room for improvement: the mean time from first medical…

DMD Features, Features, KOL

Novel Myostatin Inhibitor Is a Potential Therapeutic Agent for Duchenne Muscular Dystrophy

Kyle Habet, MD

July 6, 2021

Duchenne muscular dystrophy (DMD) is a severe, X-linked recessive dystrophinopathy caused by mutations to the DMD gene which results in abnormal dystrophin production.1,2 The mainstay of pharmacologic therapy in patients with DMD is corticosteroid treatment, which is associated with improved survival, cardiovascular and orthopedic outcomes, motor function, strength, and pulmonary function.3,4 DMD is a devastating…

Next post in DMD Features

Kyle Habet, MD

All articles by Kyle Habet, MD

Considerations for Treating Women With HAE: Lessons From a Puzzling Type 3 Case

Updated Clinical Practice Guidelines Provide Strategies for Diagnosing and Treating IPF

Lessons to Be Learned From Rare Presentations of Systemic Mastocytosis

An Often Overlooked Disease Exiting the Shadows

Bridging the Diagnostic Gap in Multiple Sclerosis

Novel Myostatin Inhibitor Is a Potential Therapeutic Agent for Duchenne Muscular Dystrophy

California Family’s Nonprofit ‘Joaquin’s Warriors’ Helps Fund Duchenne Research